Results 121 to 130 of about 20,614 (289)

Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction

, 2016
Importance  The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.
Chan, Wing W., Claggett, Brian, Deschaseaux-Voinet, Celine, Fonarow, Gregg C., Gaziano, Thomas A., McMurray, John J.V., Rouleau, Jean L., Solomon, Scott D., Turner, Stuart J., Zile, Michael R.   +9 more
core   +1 more source

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Uptitration of Sacubitril/Valsartan and Outcomes in Patients With Heart Failure　- Insight From the REVIEW-HF Registry.

Circulation Journal
BACKGROUND Guideline-directed medical therapy has become an important component of heart failure (HF) therapy, with sacubitril/valsartan as one of the recommended drugs; however, the real-world prognostic implications of sacubitril/valsartan uptitration ...
S. Doi, K. Kida, Takahito Nasu, Shunsuke Ishii, N. Kagiyama, W. Fujimoto, A. Kikuchi, T. Ijichi, T. Shibata, K. Kanaoka, S. Matsumoto, Y. Akashi   +11 more
semanticscholar   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
], Akshay S. Desai, Barry M. Massie, Claudio Borghi, for the ATMOSPHERE Committees Investigators [, Georgia Tarnesby, Henry Krum, John J.V. McMurray, Kenneth Dickstein, Lars V. Køber, M. Atif Ali, Nicola Greenlaw, Qing Shao, Scott D. Solomon, William T. Abraham, Yanntong Chiang   +15 more
core   +5 more sources

Effect of sacubitril–valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis

Frontiers in Pharmacology
Background Sacubitril–valsartan has been widely reported for reducing the risk of cardiovascular death and improving left ventricular remodeling in patients with heart failure (HF).
Yiheng Liu, Yue Sun, Weiran Dai
semanticscholar   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. [PDF]

, 2019
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Agewall, S, Rosano, GM, Spoletini, I, Vitale, C   +3 more
core   +2 more sources

Divergent Electrophysiologic Effects of Sacubitril in Digitalis- and Pinacidil-Related Shortened Repolarization: Experimental Evidence for Harmful Effects of Digitalis Glycosides

Pharmaceutics
Background: Recent studies reported an abbreviation of cardiac repolarization induced by sacubitril. Thus, the purpose of this study was to evaluate the electrophysiologic effects of sacubitril in the presence of drugs that shorten the QT interval ...
Christian Ellermann, Carlo Mengel, Julian Wolfes, Felix K. Wegner, Benjamin Rath, Florian Reinke, Lars Eckardt, Gerrit Frommeyer   +7 more
doaj   +1 more source

EFFECTIVENESS, SAFETY, AND TOLERABILITY OF SACUBITRIL/VALSARTAN OVER 3 YEARS OF FOLLOW-UP IN CANADIAN PRACTICE: INSIGHTS FROM THE PARTHENON REGISTRY [PDF]

, 2022
Michael McDonald, A. Ducharme, Justin A. Ezekowitz, J. Howlett, M. Kok, C. Rojas-Fernandez, Jacob A. Udell   +6 more
openalex   +1 more source